Navigation Links
NAMS Journal Menopause Reflects on the WHI 10 Years Later

CLEVELAND, May 30, 2012 /PRNewswire/ -- A great deal has been learned in the decade since the first results from the Women's Health Initiative (WHI) were published on July 9, 2002. The WHI was the largest and longest trial of postmenopausal women using hormone therapy (HT). The 27,000 women were prescribed estrogen-alone therapy, estrogen-progestogen therapy, or a placebo for 5 to 7 years, respectively.

Researchers expected to find that hormones prevented chronic conditions of aging in women, including heart disease. Instead, they found that hormones produced a mix of risks and benefits. The subsequent data from the WHI suggest that the risks of HT vary with a woman's age (safer if started soon after menopause).

To commemorate the 10th anniversary of this landmark trial and its voluminous reporting, the June 2012 issue of Menopause will publish an editorial by JoAnn Manson, MD, DrPH, NCMP (NAMS President) and Lubna Pal, MBBS, MRCOG, MSc, NCMP, entitled "The Women's Health Initiative: An Unforgettable Decade," along with several other timely articles:

  • "Evolution of Postmenopausal Hormone Therapy Between 2002 and 2009" by Bruce Ettinger, MD, Sharon M. Wang, PharmD, MS, R. Scott Leslie, MPH, et al.
  • "A Decade of Postmenopausal Hormone Therapy Prescribing in the United States: Long-Term Effects of the WHI" by Amy Steinkellner, PharmD, Shannon Denison, MA, Sandra Eldridge, PharmD, et al.
  • "Hormone Therapy Prescribing Trends in the Decade After the Women's Health Initiative: How Patients and Providers Have Found a Way to Sleep Better at Night" by Jennifer Corbelli, MD, Rachel Hess, MD, MS (editorial)

These articles will be available on Menopause online on May 31, 2012, at 4 pm Eastern.

Founded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field—including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education—makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit our website:

SOURCE North American Menopause Society
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
2. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
3. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
4. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
5. Elsevier Launches New Journal: Journal of Applied Research in Memory and Cognition
6. Elsevier Launches New Journal: Journal of Obsessive-Compulsive and Related Disorders
7. Journal Article Suggests DermaClose® RC Used in Combination With VAC Therapy Can Dramatically Reduce the Need for Skin Grafting of Fasciotomy Wounds for Combat Related Trauma
8. New England Journal of Medicine Article Reviews the Benefits of Ingenol Mebutate in Field Treatment of Actinic Keratoses
9. Generex Subsidiary Antigen Express Announces Publication of Review Showcasing its Proprietary Therapeutic Vaccine Technology in the Journal Vaccine
10. Data Published in the Journal of the American Society of Nephrology Shows Daily Home Hemodialysis Patients with the NxStage System One Have Significantly Lower Risk of Mortality and Improved 3-Year Survival Versus Patients on Conventional Hemodialys
11. Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... San Francisco, California (PRWEB) , ... November 27, 2015 , ... ... 1969 Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of ... 1969 at the Canterbury House at the University of Michigan in Ann Arbor. The ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point Recovery, ... together on Thanksgiving Day to share the things that they are most grateful ... Point YouTube channel, patients displayed what they wrote on index cards, describing the ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):